Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Graft Polymer (UK) PLC ( (GB:GPL) ) just unveiled an announcement.
Graft Polymer (UK) Plc has announced promising pre-clinical results in its aminoindane new chemical entity programme, co-developed with Awakn Life Sciences Corp. The study, conducted by the University of Nottingham, highlighted the compound AW21003’s potential in treating PTSD by enhancing pro-social behaviors with a favorable safety profile compared to MDMA. These findings mark a significant milestone, and the company plans to expand the programme by synthesizing additional compounds and conducting further studies, aiming to address unmet needs in PTSD treatment through ongoing collaborations.
More about Graft Polymer (UK) PLC
Graft Polymer (UK) Plc is an innovative biotechnology company focused on developing intellectual property for treating mental health and substance use disorders. The company aims to enhance outcomes for individuals with trauma-related mental health conditions, particularly PTSD, which affects millions in the US, UK, and EU markets.
YTD Price Performance: -60.34%
Average Trading Volume: 35,011,131
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £5.28M
Learn more about GPL stock on TipRanks’ Stock Analysis page.
